CTNM (Contineum Therapeutics) Total Long-Term Assets: $7.79 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CTNM Contineum Therapeutics Inc CTNM
17 GF Score
Price $15.46
! 2 Warning Signs
View Full Analysis

What is Contineum Therapeutics Total Long-Term Assets?

Contineum Therapeutics CTNM -1.37% 17 Total Long-Term Assets is $7.79 Mil as of Jun. 2026. GuruFocus rates CTNM with a GF Score™ of 17/100. The stock has 2 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Contineum Therapeutics's Total Long-Term Assets for the quarter that ended in Jun. 2026 was $7.79 Mil.

Contineum Therapeutics Total Long-Term Assets Related Terms

Contineum Therapeutics Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Contineum Therapeutics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Contineum Therapeutics Total Long-Term Assets Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
0.74 2.24 2.68 6.46 8.73

Contineum Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.05 5.92 8.73 8.38 7.79
CTNM
17GF Score
Contineum Therapeutics Inc CTNM
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Contineum Therapeutics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $7.79 Mil mean?
Contineum Therapeutics (CTNM) has a Total Long-Term Assets of $7.79 Mil as of Jun. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Contineum Therapeutics and its competitors.
Is Contineum Therapeutics' Total Long-Term Assets too high?
Contineum Therapeutics' current Total Long-Term Assets is $7.79 Mil. Overall, Contineum Therapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Contineum Therapeutics' Total Long-Term Assets compare to FDMT and PRME?
Contineum Therapeutics' Total Long-Term Assets of $7.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Contineum Therapeutics and its competitors. Contineum Therapeutics's current Total Long-Term Assets is $7.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Contineum Therapeutics stock overvalued right now?
Contineum Therapeutics (CTNM) has a current Total Long-Term Assets of $7.79 Mil. The current Total Long-Term Assets is $7.79 Mil. Contineum Therapeutics' overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Contineum Therapeutics (CTNM), the current Total Long-Term Assets is $7.79 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Contineum Therapeutics Business Description

Address 3565 General Atomics Court, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
17GF Score

Get the complete analysis for CTNM

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.46
Price